These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

61 related articles for article (PubMed ID: 8456320)

  • 21. Factor VIII-hydrolyzing IgG in acquired and congenital hemophilia.
    Wootla B; Mahendra A; Dimitrov JD; Friboulet A; Borel-Derlon A; Rao DN; Uda T; Borg JY; Bayry J; Kaveri SV; Lacroix-Desmazes S
    FEBS Lett; 2009 Aug; 583(15):2565-72. PubMed ID: 19595998
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Acquired hemophilia.
    Bouvry P; Recloux P
    Haematologica; 1994; 79(6):550-6. PubMed ID: 7896216
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Ablation of hemophilic FVIII inhibitors with FVIII priming, cyclophosphamide immune suppression, and rapid tapering of FVIII immune tolerance.
    Kobrinsky NL; Sjolander DE; Moser DK; Stegman DA
    Am J Hematol; 2004 Jun; 76(2):180-4. PubMed ID: 15164387
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The use of factor VIII/von Willebrand factor concentrate for immune tolerance induction in haemophilia A patients with high-titre inhibitors: association of clinical outcome with inhibitor epitope profile.
    Greninger DA; Saint-Remy JM; Jacquemin M; Benhida A; DiMichele DM
    Haemophilia; 2008 Mar; 14(2):295-302. PubMed ID: 18081826
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Successful immune tolerance induction with high-dose coagulation factor VIII and intravenous immunoglobulins in a patient with congenital hemophilia and high-titer inhibitor of coagulation factor VIII despite unfavorable prognosis for the therapy.
    Kubisz P; Plamenová I; Hollý P; Stasko J
    Med Sci Monit; 2009 Jun; 15(6):CS105-11. PubMed ID: 19488019
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Characterization of antibodies to factor VIII in hemophilia A patients treated by immune tolerance therapy.
    Scandella D; Reyes H; Felch M; Sakurai Y
    Haematologica; 2000 Oct; 85(10 Suppl):86-8. PubMed ID: 11187882
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The treatment of factor VIII inhibitors--a general overview.
    White GC; Roberts HR
    Vox Sang; 1996; 70 Suppl 1():19-23. PubMed ID: 8869464
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Epidemiology of inhibitors and current treatment strategies.
    Kreuz W; Ettingshausen CE; Auerswald G; Saguer IM; Becker S; Funk M; Heller C; Klarmann D; Klingebiel T;
    Haematologica; 2003 Jun; 88(6):EREP04. PubMed ID: 12826530
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Immunology of factor VIII inhibitors.
    Saint-Remy JM
    Semin Thromb Hemost; 2002 Jun; 28(3):265-8. PubMed ID: 12098086
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Current European practice in immune tolerance induction therapy in patients with haemophilia and inhibitors.
    Astermark J; Morado M; Rocino A; van den Berg HM; von Depka M; Gringeri A; Mantovani L; Garrido RP; Schiavoni M; Villar A; Windyga J;
    Haemophilia; 2006 Jul; 12(4):363-71. PubMed ID: 16834735
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Idiotypic regulation of anti-factor VIII antibodies.
    Kazatchkine MD; Lacroix-Desmazes S; Moreau A; Kaveri SV
    Haematologica; 2000 Oct; 85(10 Suppl):97-9. PubMed ID: 11187885
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Solid tumors and factor VIII antibodies.
    Hauser I; Lechner K
    Thromb Haemost; 1999 Sep; 82(3):1005-7. PubMed ID: 10494753
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The diagnosis and management of factor VIII and IX inhibitors: a guideline from the United Kingdom Haemophilia Centre Doctors Organisation.
    Hay CR; Brown S; Collins PW; Keeling DM; Liesner R
    Br J Haematol; 2006 Jun; 133(6):591-605. PubMed ID: 16704433
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effects of factor VIII concentrates on the immune system of patients with hemophilia.
    Mannucci PM
    Thromb Haemost; 1995 Jul; 74(1):437-9. PubMed ID: 8578501
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Treatment of patients with acquired inhibitors.
    Sallah S; Aledort L
    J Thromb Haemost; 2005 Mar; 3(3):595-7. PubMed ID: 15748261
    [No Abstract]   [Full Text] [Related]  

  • 36. Immunetolerance as treatment of alloantibodies to factor VIII in hemophilia. The International Registry of Immunetolerance Protocols.
    Mariani G; Scheibel E; Nogao T; Kasper CK; Ewing NP; Mauser-Bunschoten E; Ghirardini A; Bellocco R; Brackman HH
    Semin Hematol; 1994 Apr; 31(2 Suppl 4):62-4. PubMed ID: 7939781
    [No Abstract]   [Full Text] [Related]  

  • 37. Management of hemophilia patients with inhibitors.
    Hedner U; Glazer S
    Hematol Oncol Clin North Am; 1992 Oct; 6(5):1035-46. PubMed ID: 1400071
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Continuous infusion of monoclonal antibody-purified factor VIII: rational approach to serious hemorrhage in patients with allo-/autoantibodies to factor VIII.
    Gordon EM; al-Batniji F; Goldsmith JC
    Am J Hematol; 1994 Feb; 45(2):142-5. PubMed ID: 8141119
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Use of Protein-A column and porcine factor VIII.
    Rivard GE
    Haemophilia; 2002 Jan; 8 Suppl 1():20-3; discussion 28-32. PubMed ID: 11882079
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Individualised treatment of seven cases of acquired factor VIII inhibitors.
    Tien SL; Tan P; Ong YW; Loh TF
    Ann Acad Med Singap; 1991 Nov; 20(6):745-9. PubMed ID: 1803961
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.